新型固定剂量降压制剂安博诺_理论与实践_张维忠.pptVIP

新型固定剂量降压制剂安博诺? 理论与实践;降压治疗发展的总趋势; 降压治疗模式的历史演进;不同降压机制药物联合治疗的降压效应;Trials testing two pressure lowering drugs separately and in combination;不同降压机制药物联合治疗的不良反应;联合治疗减少或减轻不良反应的机制;Choose between; 在多种降压药物联合治疗方案中，ARB/HCTZ是一种双赢的联合方案。HCTZ明显提高ARB的降压幅度和速度;ARB显著减少和减轻HCTZ的不良反应。;;Reduction in BP With Combination Therapy;ARB抵销噻嗪类利尿剂的副作用;Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review; 固定剂量联合制剂通过多层次设计(Factorial Design)和效应面分析(Response surface Analyses)研究，具有合理的剂量配伍。相对于处方临时联合，固定剂量联合简化治疗药品，减少治疗费用，提高长期治疗依从性和持续性，有利于血压控制达标。;降压治疗持续性;Patient Adherence and Persistence with Antihypertensive Therapy:One- versus Two-pill Combination;Percentage of patients fully adherent to fixed-dose Combination therapy and coadministered 2-pill therapy;;The INCLUSIVE Trial The Irbesartan/HCTZ Blood Pressure Reduction in Diverse Patient Population;Minimum4 weeks;;INCLUSIVE Blood Pressure Goal Attainment at Week 2, 10, and 18 by Age Group;RAPiHD Severe Study Design, Results and Conclusions ;Study Design;;Significantly More Patients in the Combination Group Had Controlled Blood Pressure;Similar Low Rates of Laboratory Marker Abnormalities Observed in Both Treatment Groups;BP Goal Achevement in Patients with Uncontrolled Hypertension;Reductions in diastolic BP (DBP) and systolic BP (SBP) compared with baseline at 3 and 9 months in patients with mild, moderate or severe hypertension treated with a fixed combination of irbesartan 150mg /HCTZ 12.5mg once daily as first-line combination therapy;Treat-to-Target 结论